Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-11

Clinical Trial Update: 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of 3K3A-APC for amyotrophic lateral sclerosis has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 3K3A-APC (3K3A-activated protein C)

Snippet

Sponsor: Macquarie University, Australia | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2023-10-11